Georgette D. Kiser
Georgette D. Kiser's purchase track record
How the stock did after each of Georgette D. Kiser's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2022 | CVSA | $2K | +35.2% | +65.7% | -6.6% |
| 12/2/2021 | CVSA | $1K | -20.3% | +17.7% | -8.8% |
| 11/12/2021 | CVSA | $2K | -27.8% | -7.5% | -14.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Keybanc cuts Jacobs Solutions price target to $166. Keybanc maintained its Overweight rating on Jacobs Solutions but lowered its price target to $166. This adjustment comes as the stock trades near the top of its 52-week range, with an average analyst target of $162.33. The company also appeared in a list of low-volatility stocks described as risky by one analyst.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Goldman Sachs cuts NCR Voyix price target to $8. Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.
Transaction History
| AFL | ▲ Buy | Grant | 1,721 | $0 | 5/4/2026 | View on chart |
| J | ▲ Buy | Grant | 1,468 | $200K | 1/29/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 425 | $41K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,445 | $140K | 11/12/2025 | View on chart |
| AFL | ▲ Buy | Grant | 1,703 | $0 | 5/5/2025 | View on chart |
| J | ▲ Buy | Grant | 1,359 | $190K | 1/30/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,560 | $140K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 693 | $63K | 11/8/2024 | View on chart |
| AFL | ▲ Buy | Grant | 2,125 | $0 | 5/6/2024 | View on chart |
| J | ▲ Buy | Grant | 1,401 | $190K | 1/25/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 814 | $45K | 11/9/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 2,530 | $140K | 11/8/2023 | View on chart |
| VYX | ▲ Buy | Grant | 10,761 | $225K | 5/2/2023 | View on chart |
| AFL | ▲ Buy | Grant | 2,346 | $0 | 5/1/2023 | View on chart |
| J | ▲ Buy | Grant | 1,559 | $190K | 1/25/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,024 | $44K | 11/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 2,930 | $125K | 11/9/2022 | View on chart |
| AFL | ▲ Buy | Grant | 2,849 | $0 | 5/3/2022 | View on chart |
| VYX | ▲ Buy | Grant | 6,479 | $225K | 5/2/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 75 | $2K | 2/11/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 25 | $621 | 2/10/2022 | View on chart |
| J | ▲ Buy | Grant | 1,512 | $190K | 1/26/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 50 | $1K | 12/2/2021 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,213 | $38K | 11/17/2021 | View on chart |
| CVSA | ▲ Buy | Open Market | 50 | $2K | 11/12/2021 | View on chart |
| CVSA | ▲ Buy | Grant | 3,690 | $125K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Aflac Gets Mixed Analyst Views Amid Credit Rating Affirmation
Aflac received mixed updates from Wall Street, with JP Morgan raising its price target to $119 while Wells Fargo lowered its target to $116. These moves occurred alongside AM Best affirming the company's credit ratings, a factor that supports its long-term stability. The stock is currently trading near its support level, with the average analyst target sitting at $117.33.
Aflac Gets Mixed Analyst Views Amid Credit Rating Affirmation. Aflac received mixed updates from Wall Street, with JP Morgan raising its price target to $119 while Wells Fargo lowered its target to $116. These moves occurred alongside AM Best affirming the company's credit ratings, a factor that supports its long-term stability. The stock is currently trading near its support level, with the average analyst target sitting at $117.33.